Ark Invest's Third Quarter Crypto Investments and Changes

Ark Invest's Third Quarter Changes

With a focus on disruptive innovations, Ark Investment Management’s CEO Catherine "Cathie" Wood implemented a notable investment strategy in the third quarter. This period witnessed significant changes in Wood’s portfolio. Cryptocurrency companies and stocks in the technology, health, and finance sectors stood out as key areas attracting investors' attention.

New Positions and Increases

Ark Invest strengthened its portfolio during the third quarter by taking various new positions. Among the stocks acquired during this period are BitMine Immersion (BMNR), Bullish (BLSH), ATAI Life Sciences (ATAI), Pony AI (PONY), Kodiak AI (KDK), Figma (FIG), Klarna Group (KLAR), GeneDx holdings (WGS), Alibaba (BABA), Nexxen International (NEXN), and Oddity Tech (ODD).

Investors can also look at Ark Invest's significant stock increases. For example, the position in Exact Sciences (EXAS) grew by 6,072,588%, while the position in Caris Life Sciences (CAI) increased by 422%. Other notable increases include ATI Inc (ATI) at 379%, Ametek (AME) at 241%, and Alphabet (GOOG) at 153%.

Liquidated Positions

In the third quarter, Ark Invest decided to close some of its positions. The positions that were closed include Faro Technologies (FARO), Ansys (ANSS), Brainsway (BWAY), SatixFy Communication (SATX), Compugen (CGEN), and Adobe (ADBE). Additionally, among the names the fund reduced the most weight in are Guardant Health (GH) at 72%, Pagaya Technologies (PGY) at 61%, Carpenter Technologies (CRS) at 42%, Jabil (JBL) at 41%, and Robinhood (HOOD) at 36%.

Top 10 Positions

Moreover, Ark Invest's largest 10 positions are as follows:

• Recursion Pharmaceuticals (RXRX)
• Pacific Biosciences of California (PACB)
• Intellia Therapeutics (NTLA)
• Beam Therapeutics (BEAM)
• Crispr Therapeutics (CRSP)

Based on this data, it is observed that Ark Invest’s strategic changes could provide significant opportunities for investors.